Physician profile
Eric W Orlowsky
NPI 1508028713
$9,603.05
in general payments reported to CMS, 2019-2025
25 companies · $3,446 in 2025
The $3,446 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.74 · 2020: $14.12 · 2021: $50.22 · 2022: $1,262 · 2023: $2,153 · 2024: $2,660 · 2025: $3,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,154 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,153.82 |
| Education | $105.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,059.97 | 2021-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,085.85 | 2021-2025 | |
| Janssen Biotech, INC. | $865.95 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Astrazeneca Pharmaceuticals LP | $745.31 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $668.63 | 2022-2025 | |
| Ucb, INC. | $621.96 | 2022-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $610.35 | 2022-2025 | Orencia |
| Lilly USA, LLC | $543.22 | 2022-2025 | Taltz |
| Pfizer INC. | $532.55 | 2020-2025 | |
| Radius Health, INC. | $323.60 | 2022-2025 | Tymlos |
| Glaxosmithkline, LLC. | $301.00 | 2022-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $265.88 | 2022-2025 | Acthar |
| Genentech USA, INC. | $182.33 | 2022-2025 | Actemra, Rituxan, Gazyva |
| Aurinia Pharma U.S., INC. | $159.99 | 2023-2025 | Lupkynis |
| Genzyme Corporation | $120.05 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $117.23 | 2024-2025 | Purified Cortrophin Gel |
| Sandoz INC. | $85.44 | 2023-2025 | Hyrimoz |
| Horizon Therapeutics Plc | $75.52 | 2022-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $49.47 | 2024 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $44.74 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $43.24 | 2024-2025 | |
| Sobi, INC | $40.99 | 2024-2025 | |
| Tonix Medicines, INC. | $24.41 | 2025 | Tonmya |
| Hikma Pharmaceuticals USA | $18.63 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Orlowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.